Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial
Rafael Diaz,Andrés Orlandini,Noelia Castellana,Alberto Caccavo,Pablo Corral,Gonzalo Corral,Carolina Chacón,Pablo Lamelas,Fernando Botto,María Luz Díaz,Juan Manuel Domínguez,Andrea Pascual,Carla Rovito,Agustina Galatte,Franco Scarafia,Omar Sued,Omar Gutierrez,Sanjit S Jolly,José M Miró,John Eikelboom,Mark Loeb,Aldo Pietro Maggioni,Deepak L Bhatt,Salim Yusuf,ECLA PHRI COLCOVID Trial Investigators,Lorena Lopez,Juan Muntaner,Antonela Bobato,Gustavo Benavent,Diego Espinel,Sandra M Del Valle Almagro,Eleonora E Montenegro,Adrian Núñez,Lisandro Pérez Valega,Martin Christin,Leda Guzzi,Gabriela Finelli,Lilina B Schiavi,Eduardo Ferro Queirel,Luis M Moltrasio,Horacio A Fermín,Jorge V Martínez,Omar Gutiérrez,Eleonora Cunto,Pablo A Saúl,María Del Pilar Cabrera Maciel,Javier Muntaner,Damián Lerman,Paula I Truccolo,Adrián Armano,Esther V Jalife,Romina M Bertuzzi,María Inés Jean Charles,Pablo A Fernandez,Nicolás Vittal,Lucia Lampone Tappata,Diego M Murizzi,Brenda L Fernandez,Antonio Montes de Oca,Guadalupe Diaz Vega,Felipe N Queti,Luis A Calafell,Mariano Sequeira,Ricardo León de la Fuente,Julio Núñez Burgos,Sonia Del Valle Armaraz,Patricia Flores,Mariana Bellanting,Narela Blazevich,Baltasar Finucci Curi,Romina P Cabrini,Martín E Langone,Álvaro E Figueroa,Maria T Iglesias,Maria Carolina Alvero,Cesar G Lemir,José Bonorino,María Laura Pereyra,Ezequiel Barral,Mariela Rasmussen,María F Daglio,Mariano D Estofan,Francisco M Perea,Sebastián E Duhalde,María Fernanda Motta,Ignacio Romero,Guillermo Isa Massa,Celso F García,Rubén García Durán,Elena Cornejo Pucci,Silvia Saavedra,Carolina Bozikovich,Luciano Lovesio,María J Fernandez Moutin,Cristian C G Forciniti,Hugo Colombo,Nicolas Sabas,Leonardo Pilón,Adriana P Steren
DOI: https://doi.org/10.1001/jamanetworkopen.2021.41328
2021-12-01
Abstract:Importance: Hospitalized patients with COVID-19 pneumonia have high rates of morbidity and mortality. Objective: To assess the efficacy of colchicine in hospitalized patients with COVID-19 pneumonia. Design, setting, and participants: The Estudios Clínicos Latino América (ECLA) Population Health Research Institute (PHRI) COLCOVID trial was a multicenter, open-label, randomized clinical trial performed from April 17, 2020, to March 28, 2021, in adults with confirmed or suspected SARS-CoV-2 infection followed for up to 28 days. Participants received colchicine vs usual care if they were hospitalized with COVID-19 symptoms and had severe acute respiratory syndrome or oxygen desaturation. The main exclusion criteria were clear indications or contraindications for colchicine, chronic kidney disease, and negative results on a reverse transcription-polymerase chain reaction test for SARS-CoV-2 before randomization. Data were analyzed from June 20 to July 25, 2021. Interventions: Patients were assigned in a 1:1 ratio to usual care or usual care plus colchicine. Colchicine was administered orally in a loading dose of 1.5 mg immediately after randomization, followed by 0.5 mg orally within 2 hours of the initial dose and 0.5 mg orally twice a day for 14 days or discharge, whichever occurred first. Main outcomes and measures: The first coprimary outcome was the composite of a new requirement for mechanical ventilation or death evaluated at 28 days. The second coprimary outcome was death at 28 days. Results: A total of 1279 hospitalized patients (mean [SD] age, 61.8 [14.6] years; 449 [35.1%] women and 830 [64.9%] men) were randomized, including 639 patients in the usual care group and 640 patients in the colchicine group. Corticosteroids were used in 1171 patients (91.5%). The coprimary outcome of mechanical ventilation or 28-day death occurred in 160 patients (25.0%) in the colchicine group and 184 patients (28.8%) in the usual care group (hazard ratio [HR], 0.83; 95% CI, 0.67-1.02; P = .08). The second coprimary outcome, 28-day death, occurred in 131 patients (20.5%) in the colchicine group and 142 patients (22.2%) in the usual care group (HR, 0.88; 95% CI, 0.70-1.12). Diarrhea was the most frequent adverse effect of colchicine, reported in 68 patients (11.3%). Conclusions and relevance: This randomized clinical trial found that compared with usual care, colchicine did not significantly reduce mechanical ventilation or 28-day mortality in patients hospitalized with COVID-19 pneumonia. Trial registration: ClinicalTrials.gov Identifier: NCT04328480.